Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

J. Pharmacol. Exp. Ther. 307 (2): 476-480

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.


Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans

Katherine G. Moss, Guy C. Toner, Julie M. Cherrington, Dirk B. Mendel, and A. Douglas Laird

Department of Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, California (K.G.M., J.M.C., D.B.M., A.D.L.); and Department of Medical Oncology, Peter MacCallum Cancer Institute, Victoria, Australia (G.C.T.)

Abstract: Deregulated activation of the KIT receptor tyrosine kinase has been implicated in several human cancers and in inflammation, making it an attractive target for therapeutic intervention. Conversely, deficiencies in KIT signaling have been implicated in human and animal hair pigmentation disorders, reflecting a role for KIT in the development and function of melanocytes. The goal of this study was to explore the potential utility of hair depigmentation as a biological readout for systemic inhibition of KIT by SU11248 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide), an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity through targeting platelet-derived growth factor receptors, vascular endothelial growth factor receptors, KIT, and FLT3. Oral SU11248 treatment induced dose-dependent depigmentation of newly regrown hair in depilated C57BL/6 mice. Similar effects were seen after administration of a KIT-neutralizing antibody. SU11248-induced hair depigmentation was reversible with cessation of treatment. Histological and immunohistochemical evaluation of mouse skin samples supported these observations and revealed that SU11248 has no effect on levels of KIT-positive melanocytes associated with hair follicles, indicating that the inhibitory effect is at the level of melanocyte function rather than their development/survival. Similar hair depigmentation has been noted in several cancer patients receiving SU11248 in phase I trials. Strikingly, patient scalp hair exhibits bands of depigmentation and pigmentation that correspond, respectively, to periods of treatment and dosing rest periods. These data demonstrate that hair pigmentation can serve as a dose-dependent, dynamic, biological readout for KIT inhibition in mice, and, apparently, in humans.

Received for publication April 2, 2003. Accepted for publication July 29, 2003.

Address correspondence to: Dr. A. Douglas Laird, 117 16th Avenue, San Mateo, CA 94402. E-mail: douglaslaird2000{at}

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.
C. Delbaldo, S. Faivre, C. Dreyer, and E. Raymond (2012)
Therapeutic Advances in Medical Oncology 4, 9-18
   Abstract »    PDF »
New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects.
G. Aparicio-Gallego, M. Blanco, A. Figueroa, R. Garcia-Campelo, M. Valladares-Ayerbes, E. Grande-Pulido, and L. Anton-Aparicio (2011)
Mol. Cancer Ther. 10, 2215-2223
   Abstract »    Full Text »    PDF »
Phase I trial of SU14813 in patients with advanced solid malignancies.
W. Fiedler, G. Giaccone, P. Lasch, I. van der Horst, N. Brega, R. Courtney, A. Abbattista, D. R. Shalinsky, C. Bokemeyer, and E. Boven (2011)
Ann. Onc. 22, 195-201
   Abstract »    Full Text »    PDF »
Profound Hair and Skin Hypopigmentation in an African American Woman Treated With the Multi-Targeted Tyrosine Kinase Inhibitor Pazopanib.
K. Sideras, M. E. Menefee, J. K. Burton, C. Erlichman, K. C. Bible, and S. P. Ivy (2010)
J. Clin. Oncol. 28, e312-e313
   Full Text »    PDF »
Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders.
K. Schad, K. Baumann Conzett, M. C. Zipser, V. Enderlin, J. Kamarashev, L. E. French, and R. Dummer (2010)
Clin. Cancer Res. 16, 1058-1064
   Abstract »    Full Text »    PDF »
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
H. M. Prince, D. Honemann, A. Spencer, D. A. Rizzieri, E. A. Stadtmauer, A. W. Roberts, N. Bahlis, G. Tricot, B. Bell, D. J. DeMarini, et al. (2009)
Blood 113, 4819-4820
   Full Text »    PDF »
Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors.
S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering (2008)
Toxicol Pathol 36, 905-916
   Abstract »    Full Text »    PDF »
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib.
M. E. Lacouture, S. Wu, C. Robert, M. B. Atkins, H. H. Kong, J. Guitart, C. Garbe, A. Hauschild, I. Puzanov, D. T. Alexandrescu, et al. (2008)
Oncologist 13, 1001-1011
   Abstract »    Full Text »    PDF »
Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles.
V. A Randall, T. J Jenner, N. A Hibberts, I. O De Oliveira, and T. Vafaee (2008)
J. Endocrinol. 197, 11-23
   Abstract »    Full Text »    PDF »
Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas.
J. Li, J. Quirt, H. Q. Do, K. Lyte, F. Fellows, C. G. Goodyer, and R. Wang (2007)
Am J Physiol Endocrinol Metab 293, E475-E483
   Abstract »    Full Text »    PDF »
Sunitinib: From Rational Design to Clinical Efficacy.
L. Q.M. Chow and S. G. Eckhardt (2007)
J. Clin. Oncol. 25, 884-896
   Abstract »    Full Text »    PDF »
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity..
S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al. (2006)
Mol. Cancer Ther. 5, 1774-1782
   Abstract »    Full Text »    PDF »
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer.
S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, et al. (2006)
J. Clin. Oncol. 24, 25-35
   Abstract »    Full Text »    PDF »
Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
C. L. Sawyers (2003)
Genes & Dev. 17, 2998-3010
   Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882